128 related articles for article (PubMed ID: 27826154)
1. High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital Pharmacists.
Roy C; Gray C; Ruda L; Bell A; Bolt J
Can J Hosp Pharm; 2016; 69(5):367-375. PubMed ID: 27826154
[TBL] [Abstract][Full Text] [Related]
2. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
3. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.
Zobell JT; Epps K; Kittell F; Sema C; McDade EJ; Peters SJ; Duval MA; Pettit RS
J Pediatr Pharmacol Ther; 2016; 21(3):239-46. PubMed ID: 27453702
[TBL] [Abstract][Full Text] [Related]
5. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations.
Prescott WA
J Pediatr Pharmacol Ther; 2011 Oct; 16(4):262-9. PubMed ID: 22768010
[TBL] [Abstract][Full Text] [Related]
6. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
7. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.
Phillips JA; Bell SC
Intern Med J; 2001; 31(1):23-6. PubMed ID: 11478352
[TBL] [Abstract][Full Text] [Related]
8. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
9. Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
Chuk AC; Saeed F; Kousar N; Burrill S; Barns B; Rickrode G; Fu J; Katrych O; Saunders-Hao P; Block C; Lahey T
Clin Nephrol; 2015 Oct; 84(4):214-21. PubMed ID: 26308080
[TBL] [Abstract][Full Text] [Related]
10. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.
Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
J Antimicrob Chemother; 1997 Jun; 39(6):677-86. PubMed ID: 9222035
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation.
Sung L; Dupuis LL; Bliss B; Taddio A; Abdolell M; Allen U; Rolland M; Tong A; Taylor T; Doyle J
J Natl Cancer Inst; 2003 Dec; 95(24):1869-77. PubMed ID: 14679156
[TBL] [Abstract][Full Text] [Related]
12. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
Soulsby N; Bell S; Greville H; Doecke C
Intern Med J; 2009 Aug; 39(8):527-31. PubMed ID: 19220547
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis of an aminoglycoside monitoring service.
Kimelblatt BJ; Bradbury K; Chodoff L; Aggour T; Mehl B
Am J Hosp Pharm; 1986 May; 43(5):1205-9. PubMed ID: 3087162
[TBL] [Abstract][Full Text] [Related]
14. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
[TBL] [Abstract][Full Text] [Related]
15. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
Kim MJ; Bertino JS; Erb TA; Jenkins PL; Nafziger AN
J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
[TBL] [Abstract][Full Text] [Related]
16. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs.
Tabah A; De Waele J; Lipman J; Zahar JR; Cotta MO; Barton G; Timsit JF; Roberts JA;
J Antimicrob Chemother; 2015 Sep; 70(9):2671-7. PubMed ID: 26169558
[TBL] [Abstract][Full Text] [Related]
17. A practical approach enabling staff pharmacists to prospectively review and dose aminoglycoside therapy.
Possidente CJ; Lynch T
Hosp Pharm; 1988 Nov; 23(11):976-8, 981-3. PubMed ID: 10290757
[TBL] [Abstract][Full Text] [Related]
18. Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less an 6 Years Old.
Arends A; Pettit R
J Pediatr Pharmacol Ther; 2018; 23(2):152-158. PubMed ID: 29720918
[TBL] [Abstract][Full Text] [Related]
19. Validation of a dosage individualization table for extended-interval gentamicin in neonates.
Dersch-Mills D; Akierman A; Alshaikh B; Yusuf K
Ann Pharmacother; 2012; 46(7-8):935-42. PubMed ID: 22739714
[TBL] [Abstract][Full Text] [Related]
20. Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.
Higgins KL; Noda C; Stultz JS
J Pediatr Pharmacol Ther; 2018; 23(2):159-163. PubMed ID: 29720919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
